Shanghai Fosun Pharmaceutical (Group) Co., Ltd. disclosed that on 22 September 2026 it repurchased 1.20 million H shares on the Hong Kong Stock Exchange at prices ranging from HKD 18.01 to HKD 18.23 per share, translating into a volume-weighted average cost of HKD 18.16 and a total cash outlay of HKD 21.79 million.

The transaction reduced Fosun Pharma’s outstanding H-share count (excluding treasury shares) to 529.74 million, down from 530.94 million a day earlier, representing a 0.23% contraction. Concurrently, treasury shares increased to 22.20 million, while the company’s total issued share capital remained unchanged at 551.94 million shares.

The buyback forms part of a shareholder mandate approved on 16 June 2026 that authorizes repurchases of up to 54.10 million shares. Including this latest tranche, Fosun Pharma has repurchased 11.23 million shares under the mandate, equivalent to 2.08% of the share capital outstanding on the mandate date.

Under Hong Kong listing regulations, the company is restricted from issuing new shares or disposing of treasury shares until 22 October 2026, 30 days after the repurchase date.